Japan

Chugai Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Chugai Files New Drug Application in Japan for Faricimab for Diabetic Macular Edema and Neovascular Age-related Macular Degeneration

Lead Product(s): Faricimab

Therapeutic Area: Ophthalmology Product Name: RG7716

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 11, 2021

Details:

Faricimab is the first investigational bispecific antibody designed for the eye) It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) – that drive a number of retinal conditions.

Sosei Heptares

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals

Lead Product(s): Clobetasol Propionate

Therapeutic Area: Ophthalmology Product Name: APP13007

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Formosa Laboratories, Inc.

Deal Size: $2.5 million Upfront Cash: Undisclosed

Deal Type: Agreement March 11, 2021

Details:

First patient is dosed in a 370-patient in Phase 3 trial of APP13007 in the US. Sosei Heptares will receive undisclosed milestone payments based on progression of Activus' pipeline and royalties from the commercialization of certain products should they reach the market.